Browse the latest forensic toxicology articles or search the collection.
-
Muscle and Bile for Postmortem Ethanol Testing: Why Similar Averages Do Not Prove Interchangeability
A retrospective study included 177 blood–muscle and 77 blood–bile comparisons. Significant correlations and nonsignificant differences did not validate substituting these matrices for blood.
-
Can Postmortem Urine Ethanol Be Converted to Blood Ethanol? A 378-Autopsy Study
Urine ethanol exceeded blood ethanol in 86% of selected autopsies, with strong correlation. Those group findings do not establish a universal conversion or a drinking timeline.
-
Postmortem Urine EtG and EtS: Reporting Cutoffs Are Not Detection or Quantification Limits
A published HILIC–LC–MS/MS method illustrates why reporting thresholds, identification criteria and printed validation limits must be read separately before interpreting a negative biomarker.
-
Discordant Postmortem EtG and EtS Results: Why One Negative Biomarker Does Not Settle Ethanol Origin
A 79-case study found EtG-positive urine with negative EtS results. Paired biomarkers can add evidence about ethanol exposure, but do not independently quantify microbial ethanol or impairment.
-
Blind-Stick Postmortem Blood Collection: When Gastric Contamination Mimics an Overdose
A case report linked markedly elevated ethanol and amitriptyline in a blind-stick specimen to gastric contamination confirmed by cytology. Collection provenance changed the interpretation.
-
Ethanol Can Increase in a Preserved Postmortem Blood Specimen: A Serial-Testing Case
A case report documented rising ethanol despite reported fluoride preservation and cold storage. Serial results and microbial cultures require careful interpretation without a universal correction.
-
Hospital and Autopsy Cannabinoid Results: Why Three Paired Cases Do Not Supply a Correction Factor
Three cases with predeath whole blood illustrate timing, preservation and analyte-specific differences. Their values do not validate reconstruction of antemortem THC from autopsy blood.
-
Unquantifiable Postmortem THC Results Are Not Negative Tests
A validated cannabinoid method still encountered unusable postmortem specimens. Matrix interference, results below quantification limits and quantified concentrations must remain distinct.
-
Do Postmortem Drug Concentrations Always Rise With Delayed Sampling?
Repeated sampling showed increases, decreases and little change, sometimes at different sites in the same person. The results do not supply a postmortem back-calculation rate.
-
Subclavian Blood Is Not Interchangeable With Femoral Blood in Postmortem Drug Testing
A primary study found that subclavian drug concentrations could resemble heart blood more than femoral blood. Exact collection sites matter more than the label peripheral.
-
How Much Does Heterogeneity Matter in a Pediatric Lisdexamfetamine Meta-Analysis?
A historical pooled ADHD symptom effect had I² of 94%. A favorable average does not imply a uniform response across trials or individual children.
-
Does Similar Trial Dropout Prove Lisdexamfetamine Is as Safe as Placebo?
A historical adult meta-analysis found no significant discontinuation differences. Wide confidence intervals and limited safety outcomes prevent an equivalence or harmlessness claim.
-
Does an Amphetamine-Sensitive EEG Signal Mean Better Reward Learning?
A human–mouse experiment changed reward-related EEG components without demonstrating matching learning improvement. Species, dose and signal type must stay separate.
-
Why Fewer Binge-Eating Days Cannot Be Recast as a Weight-Loss Claim for Amphetamine
A historical review described lisdexamfetamine trials for binge-eating disorder. Binge days, episodes, cessation and weight change were different outcomes in selected populations.
-
Do 2,600 Virtual Patients Equal a Clinical Trial of Lisdexamfetamine?
A 2021 computational study modeled lisdexamfetamine and methylphenidate. Virtual-population size and model accuracy are not observed clinical response rates.
-
Did Lisdexamfetamine Outperform Atomoxetine in Every Functional Domain?
A historical head-to-head trial found differences in two of six parent-rated domains. Nominal significance and the selected prior-treatment population limit broad superiority claims.
-
Can Matching Published Trial Averages Replace a Head-to-Head Lisdexamfetamine Trial?
A 2024 analysis weighted data across separate trials. Matching measured characteristics can improve comparability without restoring randomized treatment assignment.
-
Can Better ADHD Ratings Coexist With More Adverse Events? A 264-Participant Amphetamine Trial
A historical pediatric trial found improved symptom ratings alongside more treatment-emergent adverse events. Efficacy and safety were distinct outcomes with distinct denominators.
-
Does a Larger Placebo-Adjusted Effect Prove an Amphetamine Dose–Response Relationship?
A historical adult trial found benefits at two doses, with a numerically larger effect at the higher dose. The doses were not statistically compared with each other.
-
Can Remission Rates Be Compared Across Different Amphetamine Trials?
Historical mixed-salts analyses used a stricter remission cutoff than a lisdexamfetamine report. Different definitions and follow-up prevent simple percentage rankings.